Showing 3381-3390 of 5646 results for "".
- Bausch Health to Purchase Majority of Synergy Pharmaceuticals’ Assets, Including Trulancehttps://modernod.com/news/bausch-health-to-purchase-majority-of-synergy-pharmaceuticals-assets-including-trulance/2479614/Bausch Health announced a deal to purchase nearly all of the assets of bankrupt drugmaker Synergy Pharmaceuticals for about $200 million in cash, with the transaction including the constipation treatment Trulance (plecanatide), according to FirstWord. Bausch Health CEO Joseph Papa noted that the
- Anthem Blue Cross Blue Shield Now Covering Avedro’s Corneal Cross-Linking Procedurehttps://modernod.com/news/anthem-blue-cross-blue-shield-now-covering-avedros-corneal-cross-linking-procedure/2479624/Avedro announced that Anthem, the largest member of the Blue Cross Blue Shield Association, has issued a positive coverage policy for Avedro’s FDA-approved corneal cross-linking procedure bringing the total number of
- Alcon Introduces New Medical Affairs Website in North America, Expanding Support for Patient Care and Clinical Communityhttps://modernod.com/news/alcon-introduces-new-medical-affairs-website-in-north-america-expanding-support-for-patient-care-and-clinical-community/2476149/Alcon recently launched a new website, AlconScience.com, for US- and Canada-based eye care professionals and academic institutions. The new medical affairs website consolidates information about Alcon’s scientific, academic, and related activities into one portal. Visitors may download clinically
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Sangamo Announces Completion of TxCell Acquisitionhttps://modernod.com/news/sangamo-announces-completion-of-txcell-acquisition/2476169/Sangamo Therapeutics announced the completion of the acquisition of TxCell, which is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of
- First Patient Successfully Implanted with Implandata’s Eye Pressure Sensor for Continual Glaucoma Monitoringhttps://modernod.com/news/first-patient-successfully-implanted-with-implandatas-eye-pressure-sensor-for-continual-glaucoma-monitoring/2476170/Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the supr
- Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usabilityhttps://modernod.com/news/eyenovia-publishes-pg21-phase-2-trial-results-examining-iop-lowering-effect-and-patient-usability/2479637/Eyenovia announced that the full results of its phase 2 PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-
- New Melanoma Treatments Do Not Supplant Surgery as First-Line Therapyhttps://modernod.com/news/new-melanoma-treatments-do-not-supplant-surgery-as-first-line-therapy/2479670/Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD), as reported in Reuters Health. “Su
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- NORA and Concussion Legacy Foundation Offer New Educational Resource on Vision Problems and Symptoms Following a Concussionhttps://modernod.com/news/nora-and-concussion-legacy-foundation-offer-new-educational-resource-on-vision-problems-and-symptoms-following-a-concussion/2479702/Following a concussion or other traumatic brain injury (TBI) there is often an interruption in communication between the eyes and the brain. Studies show that at least 50 percent of TBI patients suffer from visual dysfunctions, with one such study finding a 90 percent incidence of post-trauma vis